Residual Cardiovascular Risk in Diabetic Patients: The Role of Fibrate Statin Combination - European Medical Journal
×

Browse

Residual Cardiovascular Risk in Diabetic Patients: The Role of Fibrate Statin Combination

| Download as | PDF
Authors:
Angelos Liontos, Moses S. Elisaf, *Theodosios D. Filippatos
Disclosure:

No potential conflict of interest.

Received:
02.05.14
Accepted:
31.07.14
Citation
EMJ Diabet. ;2:83-87.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

Patients with Type 2 diabetes mellitus (T2DM) have increased cardiovascular disease (CVD) risk. The use of statins significantly reduces the rate of CVD events but many T2DM patients, especially those with mixed dyslipidaemia (MD), have residual CVD risk. The use of fibrates, which improve triglyceride and high-density lipoprotein cholesterol levels, is beneficial for the treatment of patients with MD. Evidence from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid study showed a possible beneficial effect on CVD events of the addition of fenofibrate (FF) to statin treatment in patients with T2DM and atherogenic MD. Furthermore, FF has been associated with slowing of the progression of early diabetic retinopathy. The combination of statin with a fibrate may improve the residual CVD risk and microvascular complications of patients with T2DM. However, trials specifically designed to assess the effects of fibrate-statin combination on cardiovascular outcomes in patients with T2DM are missing.

Please view the full content in the pdf above.